Literature DB >> 22012978

Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus.

S M Ghiasi1, A H Salmanian, S Chinikar, S Zakeri.   

Abstract

While Crimean-Congo hemorrhagic fever (CCHF) has a high mortality rate in humans, the associated virus (CCHFV) does not induce clinical symptoms in animals, but animals play an important role in disease transmission to humans. Our aim in this study was to examine the immunogenicity of the CCHFV glycoprotein when expressed in the root and leaf of transgenic plants via hairy roots and stable transformation of tobacco plants, respectively. After confirmatory analyses of transgenic plant lines and quantification of the expressed glycoprotein, mice were either fed with the transgenic leaves or roots, fed the transgenic plant material and injected subcutaneously with the plant-made CCHFV glycoprotein (fed/boosted), vaccinated with an attenuated CCHF vaccine (positive control), or received no treatment (negative control). All immunized groups had a consistent rise in anti-glycoprotein IgG and IgA antibodies in their serum and feces, respectively. The mice in the fed/boosted group showed a significant rise in specific IgG antibodies after a single boost. Our results imply that oral immunization of animals with edible materials from transgenic plants is feasible, and further assessments are under way. In addition, while the study of CCHF is challenging, our protocol should be further used to study CCHFV infection in the knockout mouse model and virus neutralization assays in biosafety level 4 laboratories.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22012978      PMCID: PMC3232705          DOI: 10.1128/CVI.05352-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  50 in total

Review 1.  The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa.

Authors:  H Hoogstraal
Journal:  J Med Entomol       Date:  1979-05-22       Impact factor: 2.278

2.  Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus.

Authors:  Angela J Sanchez; Martin J Vincent; Stuart T Nichol
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 3.  Therapeutic manipulation of the immune system: enhancement of innate and adaptive mucosal immunity.

Authors:  Prosper N Boyaka; Angela Tafaro; Romy Fischer; Kohtaro Fujihashi; Emilio Jirillo; Jerry R McGhee
Journal:  Curr Pharm Des       Date:  2003       Impact factor: 3.116

4.  Vaccine development strategies for improving immunization: the role of modern immunology.

Authors:  Myron M Levine; Marcelo B Sztein
Journal:  Nat Immunol       Date:  2004-05       Impact factor: 25.606

Review 5.  Mucosal immunity to infections and its importance in future vaccinology.

Authors:  Michel Lajeunesse; Qibo Zhang; Adam Finn
Journal:  Adv Exp Med Biol       Date:  2004       Impact factor: 2.622

6.  Characteristics of Crimean-Congo hemorrhagic fever virus (Xinjiang strain) in China.

Authors:  Y C Yen; L X Kong; L Lee; Y Q Zhang; F Li; B J Cai; S Y Gao
Journal:  Am J Trop Med Hyg       Date:  1985-11       Impact factor: 2.345

Review 7.  Transgenic plants as vaccine production systems.

Authors:  H S Mason; C J Arntzen
Journal:  Trends Biotechnol       Date:  1995-09       Impact factor: 19.536

8.  Enzyme-linked immunosorbent assays for the detection of antibody to Crimean-Congo haemorrhagic fever virus in the sera of livestock and wild vertebrates.

Authors:  F J Burt; R Swanepoel; L E Braack
Journal:  Epidemiol Infect       Date:  1993-12       Impact factor: 2.451

9.  Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.

Authors:  Prosper N Boyaka; Angela Tafaro; Romy Fischer; Stephen H Leppla; Kohtaro Fujihashi; Jerry R McGhee
Journal:  J Immunol       Date:  2003-06-01       Impact factor: 5.422

10.  Clinical features of Crimean-Congo haemorrhagic fever in the United Arab Emirates.

Authors:  T F Schwarz; H Nsanze; A M Ameen
Journal:  Infection       Date:  1997 Nov-Dec       Impact factor: 7.455

View more
  25 in total

1.  Crimean-Congo Hemorrhagic Fever Virus Subunit Vaccines Induce High Levels of Neutralizing Antibodies But No Protection in STAT1 Knockout Mice.

Authors:  Jeroen Kortekaas; Rianka P M Vloet; Alexander J McAuley; Xiaoli Shen; Berend Jan Bosch; Laura de Vries; Rob J M Moormann; Dennis A Bente
Journal:  Vector Borne Zoonotic Dis       Date:  2015-12       Impact factor: 2.133

Review 2.  Vaccines for viral hemorrhagic fevers--progress and shortcomings.

Authors:  Darryl Falzarano; Heinz Feldmann
Journal:  Curr Opin Virol       Date:  2013-06-15       Impact factor: 7.090

Review 3.  Plant-based vaccines against viruses.

Authors:  Edward P Rybicki
Journal:  Virol J       Date:  2014-12-03       Impact factor: 4.099

4.  Protective effects of a Modified Vaccinia Ankara-based vaccine candidate against Crimean-Congo Haemorrhagic Fever virus require both cellular and humoral responses.

Authors:  Stuart D Dowall; Victoria A Graham; Emma Rayner; Laura Hunter; Robert Watson; Irene Taylor; Antony Rule; Miles W Carroll; Roger Hewson
Journal:  PLoS One       Date:  2016-06-07       Impact factor: 3.240

Review 5.  Plant-made vaccines and reagents for the One Health initiative.

Authors:  Edward Peter Rybicki
Journal:  Hum Vaccin Immunother       Date:  2017-08-28       Impact factor: 3.452

Review 6.  Development of vaccines against Crimean-Congo haemorrhagic fever virus.

Authors:  Stuart D Dowall; Miles W Carroll; Roger Hewson
Journal:  Vaccine       Date:  2017-07-04       Impact factor: 3.641

7.  Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice.

Authors:  Jorma Hinkula; Stéphanie Devignot; Sara Åkerström; Helen Karlberg; Eva Wattrang; Sándor Bereczky; Mehrdad Mousavi-Jazi; Christian Risinger; Gunnel Lindegren; Caroline Vernersson; Janusz Paweska; Petrus Jansen van Vuren; Ola Blixt; Alejandro Brun; Friedemann Weber; Ali Mirazimi
Journal:  J Virol       Date:  2017-04-28       Impact factor: 5.103

8.  Immunization of knock-out α/β interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine.

Authors:  Nurettin Canakoglu; Engin Berber; Sukru Tonbak; Mustafa Ertek; Ibrahim Sozdutmaz; Munir Aktas; Ahmet Kalkan; Aykut Ozdarendeli
Journal:  PLoS Negl Trop Dis       Date:  2015-03-11

9.  A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model.

Authors:  Karen R Buttigieg; Stuart D Dowall; Stephen Findlay-Wilson; Aleksandra Miloszewska; Emma Rayner; Roger Hewson; Miles W Carroll
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

10.  A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease.

Authors:  S D Dowall; K R Buttigieg; S J D Findlay-Wilson; E Rayner; G Pearson; A Miloszewska; V A Graham; M W Carroll; R Hewson
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.